22494-48-0

Usage

Uses

Used in Pharmaceutical Industry:
(4'-CHLOROBIPHENYL-4-YL)-METHANOL is used as a synthetic intermediate for the development of new pharmaceuticals, leveraging its structural features to create novel drug candidates with potential therapeutic benefits.
Used in Agrochemical Industry:
In the agrochemical sector, (4'-CHLOROBIPHENYL-4-YL)-METHANOL is utilized as a precursor in the synthesis of various agrochemicals, contributing to the development of innovative products for crop protection and enhancement of agricultural yields.
Used in Materials Science:
(4'-CHLOROBIPHENYL-4-YL)-METHANOL is employed as a key component in the creation of advanced materials, taking advantage of its reactivity to produce materials with unique properties for applications in various industries.
Used in Organic Synthesis:
As a versatile building block in organic synthesis, (4'-CHLOROBIPHENYL-4-YL)-METHANOL is used to construct complex organic molecules for research and commercial purposes, driving innovation in chemical compound development.

Upstream product

• 80565-30-6 4'-chlorobiphenyl-4-carbaldehyde 
• 29540-84-9 4-chlorophenyl trifluoromethanesulfonate 
• 59016-93-2 p-hydroxymethylphenylboronic acid 
• 106-48-9 4-chloro-phenol 
• 1679-18-1 4-Chlorophenylboronic acid 
• 1122-91-4 4-bromo-benzaldehyde 
• 637-87-6 1-Chloro-4-iodobenzene 

Downstream Products

• 304693-40-1 N-(4-(4-chlorophenyl)benzyl)phthalimide 

Relevant academic research and scientific papers

CERAMIDE GALACTOSYLTRANSFERASE INHIBITORS FOR THE TREATMENT OF DISEASE

Described herein are compounds, methods of making such compounds, pharmaceutical compositions and medicaments containing such compounds, and methods of using such compounds to treat or prevent diseases or disorders associated with the enzyme ceramide galactosyltransferase (CGT), such as, for example, lysosomal storage diseases. Examples of lysosomal storage diseases include, for example, Krabbe disease and Metachromatic Leukodystrophy.

N-Heterocyclic Carbene Ligand-Controlled Chemodivergent Suzuki-Miyaura Cross Coupling

Two N-heterocyclic carbene ligands provide orthogonal chemoselectivity during the Pd-catalyzed Suzuki-Miyaura (SM) cross-coupling of chloroaryl triflates. The use of SIPr [SIPr = 1,3-bis(2,6-diisopropylphenyl)-4,5-dihydroimidazol-2-ylidene] leads to selective cross-coupling at chloride, while the use of SIMes [SIMes = 1,3-bis(2,4,6-trimethylphenyl)-4,5-dihydroimidazol-2-ylidene] provides selective coupling at triflate. With most chloroaryl triflates and arylboronic acids, ligand-controlled selectivity is high (≥10:1). The scope of this methodology is significantly more general than previously reported methods for selective SM coupling of chloroaryl triflates using phosphine ligands. Density functional theory studies suggest that palladium's ligation state during oxidative addition is different with SIMes compared to SIPr.

Preparation method and application of dimethyl acetylacetone gold

The invention relates to a preparation method and application of dimethyl acetylacetone gold. The preparation method comprises the following steps: (1) dissolving gold chloride into ethyl ether, adding methyl iodide, and stirring for 1-2 hours at the room temperature so as to obtain a reaction liquid A; (2) putting potassium tert-butoxide into acetylacetone, and stirring for 10-15 minutes at the room temperature so as to obtain a reaction liquid B; (3) at ice bath, mixing the reaction liquid A with the reaction liquid B, recovering to the room temperature naturally, carrying out a stirring reaction for 30-40 minutes, diluting with the ethyl ether, washing with water, and carrying out vacuum concentration with an organic layer (an ethyl ether layer), and carrying out vacuum drying, therebyobtaining the dimethyl (acetylacetone) gold (III).

2,6-DISUBSTITUTED PYRIDINES AS SOLUBLE GUANYLATE CYCLASE ACTIVATORS

Disclosed are compounds of formula (I) wherein R1 and R2 are independently selected from hydrogen, halo, CF3, C1-4alkyl and allyl; Y represents (II), (III), (IV) or (V) wherein R3 represents CF3 or C1-4alkyl; and R3a represents CF3 or C1-4alkyl.

Pyrimidinone compounds

Pyrimidinone compounds of formula (I) are inhibitors of the enzyme Lp-PLA2 and of use in therapy, in particular for treating atherosclerosis.